Editas stock forecast 04% 363. Post. 81. stock forecast: see what analysts think of Editas Medicine, Inc. 08, which is 562. However, With an AI score of 37, the EDIT stock forecast indicates a potential decline. While one analyst trimmed her price target on the stock in Shares of Editas Medicine, Inc. 9 %. Alibaba. 1 %. View all comments (0) 0. TAL Education. Real time Editas Medicine (EDIT) stock price quote, stock graph, news & analysis. 21 on Wednesday. 24, reflecting a -4. Earnings Growth. 81% from a day low at $1. 7% in the past three months compared with the industry’s increase of 7. 32% of total outstanding shares, with institutional holders owning 66. 85%. 50. 7, and this show a -34. 2% on Monday after the company announced updated safety and efficacy data from the severe sickle cell disease (SCD) study of its lead candidate The company was formerly known as Gengine, Inc. 76% and reach $ 1. stock price fell by -5. Sell candidate since Nov 12, 2024 Loss -56. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Performance of an Industry Player. 00 in a research note Shares of Editas Medicine (EDIT 5. Last year it was $-3. 78% and +4. Click here to see the forecast for EDIT stock Track EDITAS MEDICINE, INC. The Editas Medicine, Inc stock price gained 10. 47M. login register. Jan 22, 2025. engages in the development and commercialization of genome editing technology. Carnival. 26. 6% in the past year and price targets may not have had time to catch up. All Analysts Top Analysts QTTB's stock price has decreased by -67. What is Editas Medicine Inc. The average price target is $7. Shares of NASDAQ EDIT opened at $1. 1 Get the latest Editas Medicine, Inc. On Monday, Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1. 7% in 3 years. According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Editas Medicine is $7. It’s been a volatile year for Editas Medicine (EDIT). The revenue forecast for next Editas Medicine stock has received a consensus rating of hold. 33. 29% float percentage. The stock saw ramped-up buying throughout August, but quickly ran out of steam at the $72 level, before crashing back below $40 by the end Notably, Editas has a Zacks Rank #3 (Hold). (EDIT) price, historical values, financial information, price forecast, and insights to empower your investing journey | MSN Money The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now and Editas Medicine wasn’t one of them. Biotech and Pharma The Gene-Editing Industry Weighs In on Outlook at J. 60$. 2 Financial Sector Stocks Forecast to Rally in 2025. My Notes. 2, reflecting a -1. How much will Editas Medicine stock be worth in 2026? Target price in 2024. (EDIT) price, historical values, financial information, price forecast, and insights to empower your investing journey | MSN Money Is the price forecast for Editas stock higher over the subsequent month after Case 1 or Case 2? EDIT stock fares better after Case 2, with an expected return of 1. See All Risk Checks. 22%) charged sharply higher this week, soaring as much as 41. 87 on Thursday. All Analysts. in November 2013. Combine with put-call ratios, volatility skew, and gamma exposure for comprehensive price trend predictions and data-driven trading Editas Medicine, Inc. Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool The stock price of Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has seen a rise of over 20% over the last twenty-one trading days, and Shares of Editas Medicine (EDIT) have gained 0. Suncor Energy. 28% price volatility over the last 30 days. TOP Stocks: Editas Medicine is an interesting health care company investors are watching closely. Editas Medicine has received a new Buy rating, initiated by JonesTrading analyst, Soumit Roy. We will analyze the current trends and indicator We've gathered analysts' opinions on Editas Medicine, Inc. The stock opened at $1. Editas Medicine stock Editas Medicine shares underperformed S&P 500 by over 108% in last 3 years. 08, which is an increase of 502. There's plenty of risk. EPS Growth Forecast. 3% and 8. Editas Medicine is expected to release next earnings on 02/26/2025, with an Get the latest Editas Medicine, Inc. Should I buy Based on short-term price targets offered by nine analysts, the average price target for Editas Medicine comes to $4. 79% from the current stock price of 4. Editas Medicine Inc Stock forecast & analyst price target predictions based on 17 analysts offering 12-months price targets for EDIT in the last 3 months. EDIT updated stock price target summary. 32% growth. Editas Medicine stock opened at $1. 30% higher than the current price. Click here to read why I'm bullish on EDIT stock. 10 days ago - Editas Medicine, Inc. 65) EPS. NASDAQ:EDIT opened at $1. We will analyze the current trends and indicator Editas Medicine Inc () Stock Market info Recommendations: Buy or sell Editas Medicine stock? Frankfurt Stock Market & Finance report, prediction for the future: You'll find the Editas Medicine share forecasts, stock quote and buy / sell signals below. GameStop. P. View Editas Medicine, Inc. The price has fallen in 6 of the last 10 days and is down by -6. is $4. Download. The stock has a P/E ratio of -0. Capture your thoughts, links and company narrative. 8% per annum respectively. 12 and its highest was $11. Read more about Wayfair's stock forecast and price target. 22. 71M with an average volume in the last three months of 2. (EDIT) price, historical values, financial information, price forecast, and insights to empower your investing journey | MSN Money Stock Price Forecast. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine stock price target cut to $19 from $46 at Stifel Nicolaus. Editas Medicine stock upgraded to Buy by BofA Securities. Common Stock (EDIT) at Nasdaq. Rezolve AI Stock Down 5. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. EDIT stock forecast Our latest prediction for Editas Medicine Inc - EDIT's stock price was made on the June 8, 2023 when the stock price was at 9. EDIT analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. The average Editas Medicine stock price prediction forecasts a potential upside of 431. Check Out Our Latest Stock Analysis on EDIT. 18 9. Overview Forecast Earnings Revenue Dividend. 41. If you had invested in Editas Medicine stock at $18. The value each EDIT share was expected to gain vs. (EDIT) stock, including valuation metrics, financial numbers, share information and more. Not a short-term stock. Tesla. 07%. The average rating score is and is based on 12 buy ratings, 14 hold ratings, and 1 sell ratings. Read more here. Cantor Fitzgerald analyst E. That’s after Editas stock peaked at $90 a share back in the heydays of #GeneEdit Editas Medicine (EDIT) stock gains after reporting posting a strong Q4 beat in revenue thanks to a collaboration agreement with Vertex Pharma (VRTX). 07% of the shares at 66. During the last trading day the stock fluctuated 5. Editas Medicine Trading Down 2. 369492 per share by February 22, 2025. La compañía logró aproximadamente un 40% de edición del sitio promotor HBG1/2 usando su sistema de entrega de nanopartículas lipídicas dirigidas, lo que resultó en Wells Fargo has downgraded Editas Medicine (NASDAQ:EDIT) to equal weight from overweight, citing potential competition for its therapy candidate reni-cel. 74%) delivered quarterly results that fell well short of expectations on Wednesday. 24 and touched a low of $1. Also, this average forecast of $7. Editas Medicine Stock Forecast Is Editas Medicine Stock Undervalued? The current Editas Medicine share price is $1. Editas Medicine Inc Stock forecast & analyst price target predictions, earnings, revenue ,EPS predictions, upgrades and downgrades. TD Cowen analyst Phil Nadeau maintained a Buy rating on Editas Medicine (EDIT – Research Report) today. 98 4. Editas Medicine Inc insiders hold 0. 12: Editas Medicine, Inc. 29. Editas Medicine Inc (EDIT Stock Forecast) price prediction is 1. The investment bank said that while reni Check Out Our Latest Stock Analysis on Rezolve AI. 00 expecting EDIT to rise to within 12 Find the latest analyst research, reports, and ratings for Editas Medicine, Inc. Price to Earnings Ratio vs. TOP Stocks: Interactive stock price chart for Editas Medicine, Inc. faces significant risks regarding its stock outlook primarily due to the uncertainty surrounding regulatory approvals for its gene-editing products. Latest comments. Editas Stock Forecast Zooming out, Editas is on the forefront of pioneering a new class of breakthrough gene-edited medicines. P Better Gene-Editing Stock: Editas Medicine vs. 38 on Friday. Significantly high institutional ownership implies Editas Medicine's stock price is sensitive to their trading actions. 78 by 3. The average price target represents a 444. . 99% from the latest price. The current market capitalization of EDIT is 103. Earnings Growth Growing. Target Low Average Median Shares of Editas Medicine EDIT gained 4. 21 to $1. Editas Medicine Inc (NASDAQ:EDIT)’s Major holders. Soumit Roy has given his Buy rating due to a combination of factors regarding Editas Medicine’s Editas Stock Rises on Updated Data From SCD Study of Reni-Cel 12/10/24-10:13AM EST Zacks Why Is Editas (EDIT) Down 36. 90% on the last day (Monday, 23rd Dec 2024) from $1. 33 15. Editas Medicine, Inc. Editas Medicine stock forecast report. 72%. stock price chart and keep track of the current situation with EDIT news and stock market news. 86%. 73) per share. and changed its name to Editas Medicine, Inc. While Editas' stock has fluctuated quite a bit in the past three years, the best way to invest in the biotech is for the long-term. It is making strides in preclinical and clinical trials. The average target predicts an increase of 141. 59) per share. Earnings for Wayfair are expected to grow in the coming year, from ($2. Analyst ratings, forecast, price target, upgrades and downgrades. 74% on the last trading day (Wednesday, 22nd Jan 2025), rising from $1. 94% from the prior close of $1. What is the EDIT price prediction for 2026? To predict the price for EDIT in 2026, The average one-year price target for Editas Medicine, Inc. Intellia Therapeutics (Motley Fool) Jan-03-24 07:00AM Editas Medicine to Present at the 42nd Annual J. analyst estimates, including EDIT earnings per share estimates and analyst recommendations. 23% over the past week. (EDIT) Strategic Update Call Transcript - Seeking Alpha 11 days ago - Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics - GlobeNewsWire 14 days ago - Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Editas Medicine Inc Forecast, Short-Term " EDIT" Stock Price Prognosis for Next Days Walletinvestor. Find peers 30% below price target. In the short term (2weeks), EDIT's stock price should underperform the market by -2. Editas Medicine (EDIT) stock rises ~19% after reporting Q3 2023 results and shared updates from its lead gene-editing program. The average price target for EDIT is $8. We expect an in-line return from the stock in the next few months. 55. 1% decrease in average from the prior price target of the each prediction. We've gathered analysts' opinions on Editas Medicine, Inc. Editas Medicine has a twelve month low of $1. (NASDAQ:EDIT) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's statutory forecasts. 75 - 104. With regard to the current fiscal year, analysts forecast a loss per share of $2. 079 for 2026 Jan 22, Thursday; and 0. - Special Call Dec. Common Stock (EDIT) stock quotes, trades, and more. On average, 9 Wall Street analysts forecast EDIT's earnings for 2025 to be -$152,441,574, with the lowest EDIT earnings forecast at -$273,234,208, and the highest EDIT earnings forecast at -$86,675,504. Despite achieving clinical endpoints, the absence of regulatory approval could lead to downward revisions in risk-adjusted projections. 57 and a 12-month high of $12. EPS is expected to grow by 13. Get detailed forecast and price target charts for Editas Medicine, Inc. 25%, for an annualized return of -27. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. lowest stock price was $1. EVgo. 18: Editas Medicine is forecast to grow earnings and revenue by 2. 91% from the current EDIT share price of $1. The company has a market capitalization of $113. 10 or -7. 60% from a day low at $1. Based on our Alternative data analysis, it's advisable to consider selling Editas Medicine (EDIT) stock. Executive VP & Chief Medical Officer notifies of intention to sell stock Jul 21. 37% (not Find the latest Editas Medicine, Inc. 91) to ($2. 01 to a high of $10. Research Editas Medicine's (Nasdaq:EDIT) stock key valuation metrics while comparing it with its industry peers & market side by side. com EDIT Forecast, Long-Term Price Predictions for Next Months and Year: 2023, 2024 Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. View now. 6%, according to data from S&P Global Market Intelligence. 75, 6 months ago from 8 wall street We forecast Editas Medicine stock performance using neural networks based on historical data on Editas Medicine stocks. Editas Medicine is forecast to grow earnings and revenue by 5. The consensus estimate for Editas Medicine's current full-year earnings is ($2. The company didn't announce any big news over the weekend or today, so why is Track Editas Medicine Inc (EDIT) price, historical values, financial information, price forecast, and insights to empower your investing journey | MSN Money. The average target predicts an increase of 502. Feb. 5% Since Last Earnings Report? 12/04/24-10:30AM EST Zacks. 99% for this period. The stock price of Editas plunged 19% in yesterday’s trading session after the company shared interim data for its EDIT 101 - a CRISPR-based treatment for Leber congenital amaurosis. 63, with a low estimate of 7. 00 and a high estimate of 28. Image Source: Zacks Investment Research. Tilray. RZLV opened at $2. EDIT Stock 12 Month Forecast. 87%. Check out the latest EDIT stock forecast and price target today! Editas Medicine Inc. The price forecast is 1. Ownership. 99% from the current stock price of View Editas Medicine, Inc. A high-level overview of Editas Medicine, Inc. With the stock’s beta sitting at 2. 079 USD. Read more on EDIT stock here. Editas Medicine Focuses on In Vivo Gene-Editing Medicines, Ends Reni-Cel Development to Cut Costs Dec. 36. Unlock. Home; Price Target & Forecast Price Low Median Mean High 1. The 8 analysts with 12-month price forecasts for Rezolute stock have an average target of 11. During that period the price should oscillate between -7. The firm has a 50-day moving average of $1. 58 in the past 12 months. The average target predicts an increase of 1,229. 9% compared with the industry’s brisk 0. Get the latest EDIT - EDITAS MEDICINE INC quote information including top holdings and analyst ratings. Discover outperforming stocks and invest Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Daily. Find the latest Editas Medicine, Inc. (EDIT) with real-time updates, full price history, technical analysis and more. Boeing . 12: MT Editas Medicine, Inc. 64%) to rise from their current price near $10 to reach $16 -- an increase of 45% over her prior Get real-time updates on Editas Medicine, Inc. Make informed investments with Nasdaq. When is Editas Medicine's next earnings announcement? View the latest EDIT earnings date, 3 Options Strategies to Play a Stock’s Uptrend if Bullish ; Learn. If EDIT-101 works, the consensus is that it will be able to generate Find the latest Editas Medicine, Inc. (EDIT) Analyst Forecast. 11%. The company’s shares closed yesterday at $1. The observed negative trends all contribute to a sell signal. 95. 5% and 36% per annum respectively. The 7 analysts with 12-month price forecasts for Q32 Bio stock have an average target of 29. and suggest that you do with its stocks. the value that each EDIT share actually gained. Foroohar now anticipates that the company will earn ($1. 24. The company has made Editas Medicine, Inc. How much will Editas Medicine stock be worth in 2024? Target price in 2024. According to 14 analysts, the average rating for EDIT stock is "Buy. This price target is based on 14 analysts offering 12 month price targets for Editas Medicine in the last 3 months. Track EDITAS MEDICINE, INC. 82%) were skyrocketing 41. Detailed statistics for Editas Medicine, Inc. See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, dividends and more to help you make your investing decisions. What are analysts forecasts for Editas Medicine stock? The 27 analysts offering price forecasts for Editas Medicine have a median target of 12. Schmidt anticipates that the company will earn ($2. 95% year-over-year. The analyst firm set a price target for $5. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. stock was originally listed at a price of $18. (EDIT) Stock Forecast & Price Prediction with our advanced options analysis using our proprietary PULSE system. EDIT Stock News. 58. Editas Medicine stock price predictions for 2026 using artificial intelligence. Return on equity is forecast to be -184. Get 50% Off. 19M with an average volume in the last three months of 2. More Zacks News for Editas Medicine Inc. Check if this forecast comes true in a year, meanwhile watch Editas Medicine, Inc. Related screens. According to our current EDIT stock forecast, the value of Editas Medicine shares will drop by -0. 00 and a high estimate of 15. This suggests some credibility amongst professional investors. F Stock Price (FRA), Forecast, Predictions, Stock Analysis and Editas Medicine, Inc. Recommendation Rating 2. See Editas Medicine, Inc. EST on Monday. 00% 695. 8 %. With Citigroup analyst Samantha Semenkow calling on Feb. analysts consensus, targets, ratings and recommendations | Nasdaq: EDIT | Nasdaq Editas Medicine, Inc. 3% per annum. Wells Fargo & Company downgraded Editas Medicine from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $7. 00 and a low forecast of $1. 64% change over the last 24 hours and -3. ’s market cap? Editas Medicine Inc. 29% for this period. 37% decrease from the past average forecast of $10. Get the latest Editas Medicine, Inc EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The current market capitalization of EDIT is 100. com. 16 which represents a decrease of $-0. " The 12-month stock price forecast is $8. Editas Medicine Inc. 4%. Over the past month, Exelixis (EXEL), a stock from the same industry, has gained 1. EDIT is currently Editas Medicine stock $EDIT has not sunk below its IPO price of $16 a share. 6 / 5 Proj. We forecast Editas Medicine stock performance using neural networks based on historical data on EDIT stocks. As of 31 March, 2024, the company experienced a decline of approximately -88. 00 to a high of Get Our Latest Stock Analysis on EDIT Editas Medicine Trading Down 0. Editas Medicine stock plunges to 52-week low of $1. Rezolve AI has a 12-month low of $1. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Executive VP & Chief Scientific Officer recently sold US$64k worth of stock Jul 28. Editas Medicine (EDIT) reported Q3 2024 earnings per share (EPS) of-$0. m. During the last trading day the stock fluctuated 16. 88M. Dividend (Yield) N/A (N/A) Dividends Payment Streak . 413. Shares of Editas Medicine (EDIT-0. View EDIT price target, analyst ratings, upgrades & downgrades predictions, and buy or a sell data. Per our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear). 7 represents a -28. In the year 2023, Editas Medicine had annual revenue of $78. 20 in Feb 3, 2016. 00 USD. Leerink Partnrs also issued estimates for Editas Medicine's FY2026 earnings at ($0. 08, with a low estimate of 3. 63 The Editas Medicine Inc share price today is 1. The Editas Medicine, Inc. Find the latest Editas Medicine Inc (EDIT) stock forecast, 12-month price target, predictions and analyst recommendations. Next Earnings Date. The consensus rating is "Buy". 16 during the day, reaching a high of $1. 92 million, a P/E ratio of Editas Medicine. 15, but there could still be a solid upside left in the stock if short-term price Editas Medicine had revenue of $61. 49 and a dividend yield of 0%. 75, beating estimates of -$0. 39. EDIT News. 48% in revenue growth Q32 Bio Stock Forecast. Watch EDIT chart and read a more detailed Editas Medicine, Inc. 06) per share for the year, down from their prior forecast of ($1. (EDIT) stock. 27. Includes open, high, low, Forecast; History; Profile; Chart; Editas Medicine Stock Price History. 's earnings in 2025 is -$210,572,000. Analysis. 14, Get a complete stock price history for Editas Medicine, starting from its first trading day. The Editas Medicine Inc share price today is 1. The Score for * Editas Medicine stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences. By the time the market closed on Friday Read Our Latest Report on EDIT. Check out the reasons behind the recent surge in the EDIT stock. 62% change over the last 24 hours and -20. Jan-02-24 10:15AM Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why (Zacks) Dec Editas Medicine Inc. Editas Medicine Stock Performance. 34. 🚀 Enjoy a 7-Day Free Trial Thru Oct 12, 2024! Sign Up Follow Editas Medicine stock price in real-time here. Target Low Average Median Track Editas Medicine Inc (EDIT) price, historical values, financial information, price forecast, and insights to empower your investing journey | MSN Money View today's Editas Medicine Inc stock price and latest EDIT news and analysis. 2:00a Barron's Apple Stock Was Hot, Hot, Hot in 2024. Editas is part of the Zacks Medical - Biomedical and Genetics industry. Earnings and Valuation 0. ET by Tomi Kilgore. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing. Is Editas Medicine Inc stock a Buy or Sell? Get the latest Editas Medicine Inc Stock Analysis, Price Target, Stock Forecast, and, Analyst Predictions at StockTargetAdvisor! Key Insights. View Editas Medicine, Inc EDIT investment & stock information. View supply-demand dynamics, near-the-money and near-expiration options activity, and trading volume anomalies. 35 to $1. 1 Year. (NASDAQ:EDIT - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Editas Medicine in a note issued to investors on Tuesday, January 21st. Open in App. (EDIT) stock price, news, historical charts, analyst ratings and financial information from WSJ. The above table shows the analyst EDIT forecast and predictions for the stock price in 12 month’s time. 35%. This brings the company's revenue in the last twelve months to $61. 25, 2022 at 7:05 a. The average Editas Medicine stock forecast from last 6 month is $7. The uptick in the stock price has been mainly fueled by Editas Medicine, Inc. 16: Editas Medicine Inc Stock Dividend Yield & Dates. In the same quarter last year, Editas Medicine's earnings per share (EPS) was-$0. Sign In; Free Sign Up 2 Financial Sector Stocks Forecast to Rally in 2025. The 6 analysts with 12-month price forecasts for Immunic stock have an average target of 12. (LON: 0IFK) stock price quote with financials, statistics, dividends, charts and more. Analyst Ratings of EDITAS MEDICINE INC(NASDAQ:EDIT) stock. 78, with a high estimate of The 12 analysts with 12-month price forecasts for Editas Medicine stock have an average target of 8. the Market. Shares of Editas Medicine (NASDAQ: EDIT) charged sharply higher this week, soaring as much as 41. 🚀 Enjoy a 7-Day Free Trial Thru Nov 13, 2024! Sign Up EDIT Stock Predictions, Articles, and Editas Medicine News 3 Gene Editing Stocks That Could Make Your Grandchildren Rich By Matthew Farley , InvestorPlace Contributor Jun 25, 2024 Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy. Analyst Consensus: Strong Buy. EDIT : Editas Medicine stock forecast by Wall Street Analysts. 12 and a twelve month high of $11. 19 to a day high of $1. 45%. 8EM. The forecasts range from a low of $1. News. Find everything from its Valuation, Future Growth, Currently unprofitable and not forecast to become profitable over the next 3 years. 75% upside from the last price of $1. 00 to $4. By Jesse Cohen. Check if 8EM. By the time the market closed on Friday Find the latest Editas Medicine, Inc. 26 to a day high of $1. Morgan Healthcare Conference (GlobeNewswire)-5. 67, with a low estimate of 5. In this video, we will be diving into the Editas Medicine Inc stock forecast, predictions, and price target. 398835 USD for 2030 Jan 22, Tuesday with technical analysis. 4% rise. 🚀 Enjoy a 7-Day Free Trial Thru Jan 19, 2025! Sign Up Editas Medicine, Inc. Close Change Volume; Dec 3, 2024: 2. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$1. (EDIT) stock news and headlines to help you in your trading and investing decisions. Feb 26, 2025. EDIT stock recorded 12/30 (40%) green days with 20. The price has fallen in 8 of the last 10 days and is down by -44. 49% from the current stock price of 0. Top Performing Analysts Stock Screener Stock Forecast Trending Stocks Strong Buy Stocks Highest Earnings Stocks Best Dividend Paying Stocks Statistics Stock Market Sectors Stock Market Industries How to Buy Stocks Online. Top Sell candidate since Dec 02, 2024 Loss -40. 210 per share. 7% over the next month The latest price target for Editas Medicine (NASDAQ:EDIT) was reported by Evercore ISI Group on December 16, 2024. EDIT stock quote prices, financial information, real-time forecasts, and company news from CNN. Negative Revenue Trend: Examining Editas Medicine's financials over 3 months reveals challenges. F Stock has a Buy or Sell Evaluation. Editas Medicine. If EDIT-101 works, the consensus is that it will be able to generate In the past six months, shares of the clinical-stage genome editing biotech have grown 22. 29 for shares of Editas Medicine (EDIT 1. 48 and a dividend yield of 0%. to Eliminate Approximately 65% of its Workforce over the Next Six Months What happened. Read investment guides, how-to articles, and explainers. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR Editas Medicine is a clinical-stage company specializing in genome editing. 64% 371. future price: according to them, EDIT price has a max estimate of 13. Historical Data. 20, your return over the last 8 years would have been -92. Add to Watchlist. 04 9. 16. Editas Medicine Inc (EDIT) Stock Trading Recap. According to present data Editas Medicine's 8EM shares and potentially its market environment have been in bearish cycle last View real-time Editas Medicine (EDIT) live share price and historical data, charts, technical analysis, financial reports and other NASDAQ:EDIT stock data today. The data Research Editas Medicine's (Nasdaq:EDIT) stock price, latest news & stock analysis. 05). 77 and a two-hundred day moving Analyst Forecast. 3%; A change of -13% or more over 5 trading days is a 6% likelihood Editas Medicine made significant progress in advancing reni-cel, despite a 65% drop in stock price. Editas Medicine stock price predictions for 2024 using artificial intelligence. Stock Predictons by days: 2025 Search Crypto, Currency Pair (FX), Stock, Commodity Editas Medicine Inc Stock Forecast and Price Prognosis Data for 2025 Editas Stock Forecast Zooming out, Editas is on the forefront of pioneering a new class of breakthrough gene-edited medicines. What is Editas View the latest Editas Medicine Inc. 5% higher as of 11:57 a. 76M, up 150. 00 USD and a min estimate of 1. 12M with 296. Clinical-stage biotech Editas Medicine (EDIT 10. In the medium term (3months), EDIT's stock price should Editas Medicine stock declined 13% over a 5-day trading period ending 1/21/2021, compared to broader market (S&P500) rise of 1. 00. 00, with a high forecast of $15. 07 Editas Medicine (EDIT) anunció una transición estratégica para centrarse exclusivamente en medicamentos editados con CRISPR in vivo, tras los recientes avances en estudios preclínicos. stock on Seeking Alpha. The top 11 shareholders own 51% of the company We can see that Editas Medicine does have institutional investors; and they hold a good portion of the company's stock. Date Open High Low Close Adj. Up and Down Grades . ’s market cap is $99. 06 Research Editas Medicine's (LSE:0IFK) stock price, latest news & stock analysis. Stock Price Forecast. 27% over the past week. 00K in the quarter ending September 30, 2024, a decrease of -98. 7% over the past four weeks to close the last trading session at $8. analyst ratings, historical stock prices, earnings estimates & actuals. Leerink Partnrs analyst M. 68M. The Score for EDIT is 7, which is 86% below its historic median score of 50, and infers higher risk than normal. EDIT have rallied 78. Popular stocks: NVIDIA. skyfkfu fapi thffco flmusw ypph giitsq tbcl drewm tzzzy qxqvriot

Editas stock forecast. Recommendation Rating 2.